MYC and acute myeloid leukemia: Additionally, several groups have demonstrated that resistance to BET inhibitors in AML is mediated by the activity of β-catenin/TCF7L2/c-Myc axis, resulting in re-expression of c-Myc despite treatment with BET inhibitor89.